IMM 1.47% 34.5¢ immutep limited

Ann: Phase II study for eftilagimod alpha in COVID-19 advances, page-10

  1. 712 Posts.
    lightbulb Created with Sketch. 276
    it will be interesting to see of course how this compares to Mesoblast. MSB showed great early promise in its COVID-19 trial, to only be stopped early by the DSMB concluding that it wasn't going to meet its primary end points.

    The other issue is that if it does have statistically significantly results, whether it can get emergency approval without going to Phase 2b or Phase 3
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
34.5¢
Change
0.005(1.47%)
Mkt cap ! $501.1M
Open High Low Value Volume
34.0¢ 36.0¢ 33.5¢ $2.184M 6.253M

Buyers (Bids)

No. Vol. Price($)
5 156342 34.5¢
 

Sellers (Offers)

Price($) Vol. No.
35.0¢ 107414 4
View Market Depth
Last trade - 16.10pm 18/09/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.